Pfizer Chief Financial Officer Dave Denton to Leave — Update
By Colin Kellaher
Pfizer's chief financial officer, Dave Denton, is leaving the drugmaker to take another post in the consumer-goods industry.
Pfizer on Thursday said Denton, who joined the New York company as finance chief in May 2022, will step down from the post on Aug. 15.
Pfizer said it plans to conduct an internal and external search for a new chief financial officer, adding that Cecile Guegan, currently senior vice president of finance for its global biopharmaceutical business, will step in as interim finance chief on Aug. 16.
Guegan, 55 years old, joined Pfizer in 2005 and has been in her current post since 2022.
Denton joined Pfizer from home-improvement retailer Lowe's, where he had been chief financial officer since 2018. Prior to joining Lowe's, he spent nearly two decades with CVS, and served as finance chief before departing in connection with the union of CVS and Aetna.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 18, 2026 07:37 ET (11:37 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States